- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Pfizer believes in the metaverse: will healthcare thaw the technology's winter? | ||
| Fr | IMPACT ovarian cancer capsules authorised in China | ||
| Fr | Ozempic named in latest Medicare price negotiations | ||
| Fr | HEOR explained: Improving healthcare decisions with real-world evidence | ||
| Fr | Mega M&A at JP Morgan Conference 2025 - is biopharma M&A poised for a rebound? | ||
| Fr | Charles River and Akron link to integrate cytokines into cell therapy | ||
| Fr | FDA beats EMA to most approved new drugs in 2024 | ||
| Fr | COPD market to expand with AstraZeneca's focus on biologics and strong portfolio growth | ||
| Fr | Leading Sales and Marketing Intelligence Providers and Technology Solutions for the Pharmaceutical Industry | ||
| Fr | CDE grants BTD to Innovent's IBI343 for pancreatic cancer | ||
| Do | JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly's low revenue forecast | ||
| Do | JP Morgan 2025: Radiopharmaceuticals M&A fuels Telix's busy year | ||
| Do | European supergroup launches to tackle diversity in clinical trials | ||
| Do | Meridian Medical wins $129m US gov contract for nerve agent antidote supply | ||
| Do | Santhera launches DMD therapy in the UK following NICE nod | ||
| Do | Lyndra and Thermo Fisher partner for oral therapies | ||
| Do | InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS | ||
| Do | JP Morgan 2025: GoodRx takes aim at US drug pricing challenges | ||
| Do | Designing clinical trials for a complex disease: pediatric obesity | ||
| Do | Be Bio secures $92m for haemophilia B and hypophosphatasia treatments | ||
| Do | Lilly gains US FDA approval for Omvoh to treat Crohn's disease | ||
| 15.01. | Charles River CEO reveals drop in 2025 revenue outlook at JP Morgan | ||
| 15.01. | Regenxbio and Nippon Shinyaku forge $810m gene therapy deal | ||
| 15.01. | JP Morgan 2025: AstraZeneca promises a 'catalyst-rich' year ahead | ||
| 15.01. | Insmed's gene therapy poised to challenge DMD landscape after IND clearance |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
